Cargando…
Intradermal administration of DNA vaccine targeting Omicron SARS-CoV-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction
Emerging SARS-CoV-2 Omicron variants are highly contagious with enhanced immune escape mechanisms against the initially approved COVID-19 vaccines. Therefore, we require stable alternative-platform vaccines that confer protection against newer variants of SARS-CoV-2. We designed an Omicron B.1.1.529...
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415318/ https://www.ncbi.nlm.nih.gov/pubmed/37563266 http://dx.doi.org/10.1038/s41598-023-40172-y |
| _version_ | 1785087509940666368 |
|---|---|
| author | Hayashi, Hiroki Sun, Jiao Yanagida, Yuka Otera, Takako Tai, Jiayu A. Nishikawa, Tomoyuki Yamashita, Kunihiko Sakaguchi, Naoki Yoshida, Shota Baba, Satoshi Chang, Chin Yang Shimamura, Munehisa Okamoto, Sachiko Amaishi, Yasunori Chono, Hideto Mineno, Junichi Rakugi, Hiromi Morishita, Ryuichi Nakagami, Hironori |
| author_facet | Hayashi, Hiroki Sun, Jiao Yanagida, Yuka Otera, Takako Tai, Jiayu A. Nishikawa, Tomoyuki Yamashita, Kunihiko Sakaguchi, Naoki Yoshida, Shota Baba, Satoshi Chang, Chin Yang Shimamura, Munehisa Okamoto, Sachiko Amaishi, Yasunori Chono, Hideto Mineno, Junichi Rakugi, Hiromi Morishita, Ryuichi Nakagami, Hironori |
| author_sort | Hayashi, Hiroki |
| collection | PubMed |
| description | Emerging SARS-CoV-2 Omicron variants are highly contagious with enhanced immune escape mechanisms against the initially approved COVID-19 vaccines. Therefore, we require stable alternative-platform vaccines that confer protection against newer variants of SARS-CoV-2. We designed an Omicron B.1.1.529 specific DNA vaccine using our DNA vaccine platform and evaluated the humoral and cellular immune responses. SD rats intradermally administered with Omicron-specific DNA vaccine via pyro-drive jet injector (PJI) thrice at 2-week intervals elicited high antibody titers against the Omicron subvariants as well as the ancestral strain. Indeed, the Omicron B.1.1.529-specific antibody titer and neutralizing antibody were higher than that of other strains. Longitudinal monitoring indicated that anti-spike (ancestral and Omicron) antibody titers decreased toward 30 weeks after the first vaccination dose. However, neutralization activity remained unaltered. Germinal center formation was histologically detected in lymph nodes in rats immunized with Omicron DNA vaccine. Ancestral spike-specific immune cell response was slightly weaker than Omicron spike-specific response in splenocytes with Omicron-adapted DNA vaccine, evaluated by ELISpot assay. Collectively, our findings suggest that Omicron targeting DNA vaccines via PJI can elicit robust durable antibody production mediated by germinal center reaction against this new variant as well as partially against the spike protein of other SARS-CoV-2 variants. |
| format | Online Article Text |
| id | pubmed-10415318 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104153182023-08-12 Intradermal administration of DNA vaccine targeting Omicron SARS-CoV-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction Hayashi, Hiroki Sun, Jiao Yanagida, Yuka Otera, Takako Tai, Jiayu A. Nishikawa, Tomoyuki Yamashita, Kunihiko Sakaguchi, Naoki Yoshida, Shota Baba, Satoshi Chang, Chin Yang Shimamura, Munehisa Okamoto, Sachiko Amaishi, Yasunori Chono, Hideto Mineno, Junichi Rakugi, Hiromi Morishita, Ryuichi Nakagami, Hironori Sci Rep Article Emerging SARS-CoV-2 Omicron variants are highly contagious with enhanced immune escape mechanisms against the initially approved COVID-19 vaccines. Therefore, we require stable alternative-platform vaccines that confer protection against newer variants of SARS-CoV-2. We designed an Omicron B.1.1.529 specific DNA vaccine using our DNA vaccine platform and evaluated the humoral and cellular immune responses. SD rats intradermally administered with Omicron-specific DNA vaccine via pyro-drive jet injector (PJI) thrice at 2-week intervals elicited high antibody titers against the Omicron subvariants as well as the ancestral strain. Indeed, the Omicron B.1.1.529-specific antibody titer and neutralizing antibody were higher than that of other strains. Longitudinal monitoring indicated that anti-spike (ancestral and Omicron) antibody titers decreased toward 30 weeks after the first vaccination dose. However, neutralization activity remained unaltered. Germinal center formation was histologically detected in lymph nodes in rats immunized with Omicron DNA vaccine. Ancestral spike-specific immune cell response was slightly weaker than Omicron spike-specific response in splenocytes with Omicron-adapted DNA vaccine, evaluated by ELISpot assay. Collectively, our findings suggest that Omicron targeting DNA vaccines via PJI can elicit robust durable antibody production mediated by germinal center reaction against this new variant as well as partially against the spike protein of other SARS-CoV-2 variants. Nature Publishing Group UK 2023-08-10 /pmc/articles/PMC10415318/ /pubmed/37563266 http://dx.doi.org/10.1038/s41598-023-40172-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Hayashi, Hiroki Sun, Jiao Yanagida, Yuka Otera, Takako Tai, Jiayu A. Nishikawa, Tomoyuki Yamashita, Kunihiko Sakaguchi, Naoki Yoshida, Shota Baba, Satoshi Chang, Chin Yang Shimamura, Munehisa Okamoto, Sachiko Amaishi, Yasunori Chono, Hideto Mineno, Junichi Rakugi, Hiromi Morishita, Ryuichi Nakagami, Hironori Intradermal administration of DNA vaccine targeting Omicron SARS-CoV-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction |
| title | Intradermal administration of DNA vaccine targeting Omicron SARS-CoV-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction |
| title_full | Intradermal administration of DNA vaccine targeting Omicron SARS-CoV-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction |
| title_fullStr | Intradermal administration of DNA vaccine targeting Omicron SARS-CoV-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction |
| title_full_unstemmed | Intradermal administration of DNA vaccine targeting Omicron SARS-CoV-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction |
| title_short | Intradermal administration of DNA vaccine targeting Omicron SARS-CoV-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction |
| title_sort | intradermal administration of dna vaccine targeting omicron sars-cov-2 via pyro-drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415318/ https://www.ncbi.nlm.nih.gov/pubmed/37563266 http://dx.doi.org/10.1038/s41598-023-40172-y |
| work_keys_str_mv | AT hayashihiroki intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT sunjiao intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT yanagidayuka intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT oteratakako intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT taijiayua intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT nishikawatomoyuki intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT yamashitakunihiko intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT sakaguchinaoki intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT yoshidashota intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT babasatoshi intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT changchinyang intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT shimamuramunehisa intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT okamotosachiko intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT amaishiyasunori intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT chonohideto intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT minenojunichi intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT rakugihiromi intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT morishitaryuichi intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction AT nakagamihironori intradermaladministrationofdnavaccinetargetingomicronsarscov2viapyrodrivejetinjectorprovidestheprolongedneutralizingantibodyproductionviagerminalcenterreaction |